Last 8,670 KRW
Change Today +70.00 / 0.81%
Volume 102.9K
As of 2:10 AM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

daehwa pharm co ltd (067080) Snapshot

Open
8,580
Previous Close
8,600
Day High
8,820
Day Low
8,500
52 Week High
10/23/14 - 9,250
52 Week Low
11/8/13 - 5,750
Market Cap
158.0B
Average Volume 10 Days
151.5K
EPS TTM
95.00
Shares Outstanding
18.2M
EX-Date
06/27/14
P/E TM
91.3x
Dividend
100.00
Dividend Yield
1.15%
Current Stock Chart for DAEHWA PHARM CO LTD (067080)

Related News

No related news articles were found.

daehwa pharm co ltd (067080) Related Businessweek News

No Related Businessweek News Found

daehwa pharm co ltd (067080) Details

DAE HWA Pharmaceutical Co., Ltd. develops, manufactures, and supplies medicines primarily in South Korea. The company offers analgesics and anti-inflammatory drugs, and antipyretics; central nervous system drugs; corticosteroids; respiratory drugs; drugs for liver diseases; hemorrhoids; vitamins and tonics; injections; antibiotics; plasters; antihistamines; skeletal muscle relaxants; cardiovascular drugs; anti-inflammatory enzymes; gastro-intestinal drugs; health food products; topical drugs; injections; and other products. It also provides transdermal drug delivery system, a pharmaceutical preparation that can be applied on the intact skin for systemic absorption; and active pharmacological ingredients. DAE HWA Pharmaceutical Co., Ltd. exports its products to approximately 15 countries. The company supplies products primarily to pharmacies and hospitals. DAE HWA Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Seoul, South Korea.

Founded in 1984

daehwa pharm co ltd (067080) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daehwa pharm co ltd (067080) Key Developments

DAE HWA Pharmaceutical Co., Ltd., Annual General Meeting, Mar 21, 2014

DAE HWA Pharmaceutical Co., Ltd., Annual General Meeting, Mar 21, 2014., at 10:00 Korea Standard Time. Location: beef in Gangwon hoengseongeup. Agenda: To consider audit of the audit report; to consider business report; to consider the approval of the connection and separate financial statements; to consider dividend of KRW 50 per share; to consider appointment of directors; to consider standing auditor; to consider remuneration of directors; to consider approval of the remuneration of the audit; and to consider other references concerning investment decisions.

DAE HWA Pharmaceutical Co., Ltd. Presents at 2013 BIO International Convention, Apr-24-2013 10:45 AM

DAE HWA Pharmaceutical Co., Ltd. Presents at 2013 BIO International Convention, Apr-24-2013 10:45 AM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.

Dae Hwa Pharmaceutical Co., Ltd Proposes Dividend

Dae Hwa Pharmaceutical Co., Ltd. to propose dividend per share, 50 face value of 10%, for the year 2012 at its AGM to be held on March 22, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
067080:KS 8,670.00 KRW +70.00

067080 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 067080.
View Industry Companies
 

Industry Analysis

067080

Industry Average

Valuation 067080 Industry Range
Price/Earnings 100.0x
Price/Sales 1.1x
Price/Book 2.4x
Price/Cash Flow 101.5x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEHWA PHARM CO LTD, please visit www.dhpharm.co.kr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.